For the year ending 2025-12-31, ASMB had $20,106K increase in cash & cash equivalents over the period. -$41,159K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Collaboration revenue from a related party | 72,303 |
| Total research and development | 64,813 |
| General and administrative | 19,608 |
| Interest and other income, net | 5,996 |
| Income tax expense | 0 |
| Net loss | -6,122 |
| Depreciation and amortization | 129 |
| Stock-based compensation | 4,677 |
| Net accretion of investments in marketable debt securities | 2,346 |
| Non-cash rent expense | 851 |
| Realized gain on investments in marketable debt securities | 3 |
| Accounts receivable from collaboration | 974 |
| Prepaid expenses and other current assets | 2,045 |
| Accounts payable | 586 |
| Accrued research and development expenses | 114 |
| Other accrued expenses | 887 |
| Deferred revenue from a related party | -36,096 |
| Operating lease liabilities | -751 |
| Net cash used in operating activities | -41,093 |
| Proceeds from maturities of marketable securities | 116,432 |
| Purchases of marketable securities | 229,834 |
| Purchases of property and equipment | 66 |
| Net cash (used in) provided by investing activities | -113,468 |
| Proceeds from the issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs | 123,600 |
| Proceeds from the issuance of common stock and warrants in private placements to a related party, net of issuance costs | 42,785 |
| Proceeds from the exercise of warrants | 5,510 |
| Proceeds from the issuance of common stock under atm equity offering program, net of issuance costs | 1,922 |
| Proceeds from the issuance of common stock under espp | 725 |
| Proceeds from the exercise of stock options | 125 |
| Proceeds from the issuance of common stock and warrants in a registered direct offering, net of issuance costs | 0 |
| Net cash provided by financing activities | 174,667 |
| Net increase in cash and cash equivalents | 20,106 |
| Cash and cash equivalents at the beginning of the year | 38,344 |
| Cash and cash equivalents at the end of the year | 58,450 |
ASSEMBLY BIOSCIENCES, INC. (ASMB)
ASSEMBLY BIOSCIENCES, INC. (ASMB)